Curis to Present at the Rodman & Renshaw 6th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the company will be presenting at the Rodman & Renshaw Annual Global Investment Conference at 5:20 p.m. EDT (12:20 p.m. local time) on May 17, 2010, in London.

Dan Passeri, Curis’ President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor. GDC-0449 is currently being developed in three Phase II clinical trials by Curis’ collaborator Genentech, including in a pivotal Phase II trial in advanced basal cell carcinoma and Phase II trials in metastatic colorectal cancer and advanced ovarian cancer. Mr. Passeri will also discuss CUDC-101, Debio 0932 and Curis' other targeted cancer programs, in addition to other corporate activities.

There will be a corresponding webcast of the presentation, which can be accessed by visiting:

http://www.wsw.com/webcast/rrshq17/cris

The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at www.curis.com.



CONTACT:

Curis, Inc.
Michael P. Gray, 617-503-6632
CFO & COO
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Genetics  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.